On Monday July 6th, the nanoHUB will be intermittently unavailable due to scheduled maintenance. We apologize for any inconvenience this may cause. close

Support

Support Options

Submit a Support Ticket

 

Tags: cancer

Online Presentations (21-40 of 77)

  1. [Illinois] Cancer Community Symposium 2012: The Inhibitory Effects of the Antifibrotic Drug Halofuginone on Uterine Leiomyoma Smooth Muscle Cells

    09 May 2012 | Online Presentations | Contributor(s): Faezeh Koohestani

    Uterine leiomyomas are the most prevalent benign tumors of the reproductive tract in women. Available treatments for leiomyomas are limited to surgical procedures or hormonal therapy, which are...

    https://nanohub.org/resources/13943

  2. [Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling

    09 May 2012 | Online Presentations | Contributor(s): Elvira de Mejia

    Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling Lunasin is a...

    https://nanohub.org/resources/13942

  3. [Illinois] Cancer Community Symposium 2012: A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)

    09 May 2012 | Online Presentations | Contributor(s): Jennifer Stone

    Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result...

    https://nanohub.org/resources/13941

  4. [Illinois] Cancer Community Symposium 2012: Micro-western Arrays for Identification of Novel Mechanisms Underlying Resistance of Cancer Cells to Chemotherapeutic Agents

    09 May 2012 | Online Presentations | Contributor(s): Richard B. Jones

    A fundamental goal in cancer treatment is the delivery of therapeutics in a manner that takes into consideration genetic differences between individuals. Genome-wide association analyses have...

    https://nanohub.org/resources/13940

  5. [Illinois] Cancer Community Symposium 2012: DriveRank: Discovering Patient-Specific Driver Mutations

    09 May 2012 | Online Presentations | Contributor(s): Jack Pu Hou

    One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations)....

    https://nanohub.org/resources/13939

  6. [Illinois] Cancer Community Symposium 2012: Elevated Estrogen Signaling Drives Tumorigenesis in a Novel Animal Model for Ovarian Epithelial Cancer

    09 May 2012 | Online Presentations | Contributor(s): Mary Jo Laws

    We generated a mouse model where aberrant estrogen receptor alpha (Esr1) signaling in the hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this model, termed Esr1d/d, the Esr1...

    https://nanohub.org/resources/13938

  7. [Illinois] Cancer Community Symposium 2012: An Integrated Approach to Cancer Research

    09 May 2012 | Online Presentations | Contributor(s): John F. McDonald

    The field of cancer biology is rapidly moving from an era of specialization to an era of integration. In my presentation, I will provide examples of the integration of molecular biology with...

    https://nanohub.org/resources/13937

  8. [Illinois] Cancer Community Symposium 2012: Closing Address and Awards

    09 May 2012 | Online Presentations | Contributor(s): Rohit Bhargava

    Jaeyun Sung announces the awards from the poster sessions. Dr. Rohit Bhargava provides the audience with reflections on the conference and thoughts going forward. Cancer Community At Illinois...

    https://nanohub.org/resources/13936

  9. KIST/PU Nanostructured Heparin Derivatives as an Angiogenesis Inhibitor

    07 Dec 2011 | Online Presentations | Contributor(s): Youngro Byun

    Although low molecular weight heparin (LMWH) has been known to regulate angiogenesis, tumor growth and metastasis, the administration of heparin for treating cancer is limited in clinical...

    https://nanohub.org/resources/12651

  10. KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?

    06 Dec 2011 | Online Presentations | Contributor(s): J. Paul Robinson

    Outline: Outline the Professors Dilemma Show what the normal criteria for research project direction is Discuss the Corporate perspective Discuss an example of failed innovation Demonstrate...

    https://nanohub.org/resources/12652

  11. KIST/PU Designing a Research Program Around Unmet Clinical Needs

    06 Dec 2011 | Online Presentations | Contributor(s): Alyssa Panitch

    Dr. Panitch specializes in bioorganic chemistry, controlled release and materials and peptide therapeutics. Her research interests include the design and synthesis of biomaterials for drug...

    https://nanohub.org/resources/12650

  12. KIST/PU Theragnosis – A New Paradigm of Personalized Medicine

    06 Dec 2011 | Online Presentations | Contributor(s): Ick Chan Kwon

    Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues...

    https://nanohub.org/resources/12649

  13. Illinois BioNanotechnology Seminar Series Fall 2011: Precisely Size Controlled Drug-silica Nanoconjugate for Cancer Therapy

    05 Dec 2011 | Online Presentations | Contributor(s): Li Tang

    Drug delivery nanomedicine, exemplified by micelles and nanoparticles roughly in the size range of 1-200 nm, have attracted much interest in the past 2-3 decades as alternative modalities for...

    https://nanohub.org/resources/12440

  14. Illinois BioNanotechnology Seminar Series Fall 2011: Deconvolving Stiffness in MEMS Pedestal Cell Mass Measurements

    05 Dec 2011 | Online Presentations | Contributor(s): Elise Corbin

    The complex relationships between a cell's behavior and the physical properties of both itself and its environment have long been of interest. Specifically, the understanding the mechanisms...

    https://nanohub.org/resources/12445

  15. BME 695L Special Lecture 3: In vivo Model Systems to Study Nanomedical Approaches to Cancer Detection and Intervention

    02 Dec 2011 | Online Presentations | Contributor(s): Deborah W Knapp

    Guest lecturer: Deborah Knapp.

    https://nanohub.org/resources/12622

  16. Illinois 2011 NanoBiophotonics Summer School: Poster Day: Hadiyah Nicole Green

    29 Nov 2011 | Online Presentations | Contributor(s): Hadiyah Nicole Green, Nadia Jassim

    Cancer laser treatment using gold nanorods.

    https://nanohub.org/resources/12529

  17. BME 695L Lecture 13: Designing Nanomedical Systems (NMS) for In-vivo Use

    22 Nov 2011 | Online Presentations | Contributor(s): James Leary

    See references below for related reading. 13.1      Bringing in-vivo considerations into NMS design 13.1.1    the in-vitro to ex-vivo to...

    https://nanohub.org/resources/12495

  18. BME 695L Lecture 14: Designing and Testing Integrated Nanomedical Systems

    22 Nov 2011 | Online Presentations | Contributor(s): James Leary

    See references below for related reading. 14.1      Introduction to integrated designs 14.1.1    “Total design” but there is some order in...

    https://nanohub.org/resources/12496

  19. Illinois BioNanotechnology and Nanomedicine: Applications in Cancer and Mechanobiology Lecture 19: How can you tell if a cell is cancerous?

    14 Nov 2011 | Online Presentations | Contributor(s): Catherine J. Murphy

    Lecture by Catherine Murphy.

    https://nanohub.org/resources/12488

  20. Illinois BioNanotechnology and Nanomedicine: Applications in Cancer and Mechanobiology Lecture 20: Nanoparticle contrast agents for tissue

    14 Nov 2011 | Online Presentations | Contributor(s): Catherine J. Murphy

    Lecture by Catherine Murphy.

    https://nanohub.org/resources/12489

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.